Suggested remit - To appraise the clinical and cost effectiveness of mogamulizumab within its marketing authorisation for treated mycosis fungoides or Sézary syndrome T-cell lymphoma
Status In progress
Process STA 2018
ID number 1405

Provisional Schedule

Expected publication 26 August 2020

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
09 May 2019 - 07 June 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
27 March 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of mogamulizumab for previously treated cutaneous T-cell lymphoma (mycosis fungoides or Sézary syndrome). Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early October 2019 when we will write to you about how you can get involved.
07 June 2018 This appraisal has been rescheduled following an update from the company. The appraisal is now anticipated to begin in early July 2019 with a submission deadline anticipated late August/early September 2019. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.
12 March 2018 - 11 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance